Bio-Techne

Phase A — Understand the business

Lens 1 · Company Overview

Bio-Techne is a life-science "picks-and-shovels" supplier — it sells reagents, instruments, and services into research, diagnostics, and bioprocessing; it does not sell drugs or run clinical trials. Founded 1976 (Minneapolis, MN), public since 1985. The genomics "beat" tag undersells it: this is a diversified consumables-and-tools franchise whose single largest exposure is proteins/antibodies, not sequencing.

Two reported segments:

• Protein Sciences (~72% of FY25 sales, $870.2M) — two divisions. Reagent Solutions (cytokines, growth factors, antibodies, small molecules; brands R&D Systems, Tocris, Novus; "world leader in high-quality proteins" incl. cGMP grade for cell & gene therapy). Analytical Solutions (automated protein analysis / Simple Western / multiplexed immunoassays; brand ProteinSimple). This is the high-margin razor-blade core.
• Diagnostics & Spatial Biology (~28%, $346.3M) — Spatial Biology (Advanced Cell Diagnostics / RNAscope in-situ hybridization + Lunaphore COMET hyperplex instrument), Molecular Diagnostics (Exosome Diagnostics ExoDx Prostate, Asuragen), Diagnostic Reagents (OEM controls/calibrators).

Customers: academic + government research labs, pharma/biotech, CROs, and diagnostic-instrument OEMs. Concentration is low — "no single end-user customer accounted for more than 10%" of either segment's sales in FY25/24/23. Revenue model: point-in-time product sales (consumables + instruments), not recurring contracts — KPMG flags net-sales recognition as the critical audit matter precisely because revenue is dispersed across many small transactions and locations. ~44% of FY25 sales are ex-US. Distribution partly direct, partly via a distribution agreement with Thermo Fisher Scientific.

Lens 2 · Supply Chain

Upstream → company → customer, named where the filing names them (the filing is deliberately vague on individual suppliers — "no single supplier is material" — so chokepoints are structural, not single-name):

• Upstream inputs: electronic components, chemicals, and biological materials (sera, cell lines, raw proteins). The 10-K explicitly states no single supplier is material but concedes that for components needing particular specifications/qualifications "there may be a single supplier or a limited number of suppliers"; mitigation = safety stock, alternative materials, multi-sourcing.
• Manufacturing (the moat node): Bio-Techne manufactures most of its hundreds of thousands of products itself, in North America plus the UK, Canada, Switzerland (Lunaphore), and China. Consumables ship within ~1 day of order; instruments + cartridges within 1–2 weeks; no significant backlog.
• Key named partners / stakeholders along the chain:
• Thermo Fisher Scientific — distribution agreement (channel) AND exclusive licensee of the ExoTRU kidney-transplant-rejection test.
• Wilson Wolf Corporation — 19.9% owned; supplies G-Rex cell-culture devices; jointly markets via the ScaleReady venture for cell & gene therapy.
• Third-party distributors in China, Japan, Eastern Europe, rest-of-world.
• End customers: research scientists (academia/government — funding-sensitive), pharma/biotech R&D and QC departments, diagnostic OEMs, and (for ExoDx) prescribing physicians.

Chokepoint read: the real single-source dependency is Bio-Techne itself — in-house manufacture of proprietary biological content is the asset, which is exactly why Merck wants it. Input-side fragility is low; demand-side fragility (academic/biotech funding) is the binding constraint, not supply.

Lens 3 · Competitive Advantages (moats)

• Catalogue breadth + brand as the standard. R&D Systems is the reference brand for cytokines/growth factors; cited in literature for decades. Switching cost in research reagents is reproducibility — a lab that validated an assay on an R&D Systems antibody will not casually swap it, because a new lot/vendor reopens validation. That is a quiet but durable switching cost.
• Razor/razor-blade in Analytical + Spatial. ProteinSimple (Simple Western/Jess), Lunaphore COMET, and ACD RNAscope place instruments that pull recurring consumable/cartridge revenue. COMET grew >65% in Q3 FY26 — the install base is compounding.
• IP estate: ~1,340 granted patents + ~270 pending as of 2025-06-30; trade-secret protection on Reagent Solutions formulations.
• cGMP-grade proteins for cell & gene therapy — a regulatory-qualified supply position competitors cannot trivially replicate (it requires audited facilities + a track record).
• Bargaining power: strong over the long tail of academic buyers (specialized, low-substitutability reagents); weaker against large pharma procurement and against its own distribution partner Thermo Fisher. Limited pricing power was visible in FY26 — organic revenue went negative despite price actions, because volume fell with funding.

Moat verdict: real but narrow-and-eroding-at-the-edges. The reagent core is genuinely defensible (the reason a strategic paid 36%); the instruments and diagnostics franchises are competitive and cyclical. This is a B+ moat, not the A-moat of a Danaher-style razor-blade compounder.

Lens 4 · Segments

Revenue by segment, FY (year ended June 30), all:

Trend & cause:

• FY25 was a re-acceleration: consolidated +5% (all organic; FX immaterial). Protein Sciences +5% organic on proteomic analytical + cell-therapy strength; D&SB +6% organic on molecular diagnostics + Lunaphore.
• FY26 is a re-deceleration / contraction. Q3 FY26 (qtr ended 2026-03-31): consolidated net sales $311.4M, down ~1.5% reported, −2% organic. Protein Sciences Q3 organic −4% (FX +3% masked it to −1% reported); D&SB organic +3% but reported −4% after the 8% Exosome-divestiture drag. Nine-month FY26 consolidated revenue $893.8M vs $902.7M — a year-over-year decline.
• Geography: ~44% ex-US; FX exposure euro 15% / GBP 4% / CNY 5% / CAD 3% / CHF 1% of sales.
• Segment profitability divergence: Protein Sciences operating margin ~44% (Q3 FY26) vs D&SB ~12% — the protein core is the earnings engine; D&SB is the growth-optionality/margin-drag book that just got cleaner via the Exosome sale.

The segment story is the deal logic: a high-margin reagent core decelerating under a macro funding shock, with a sub-scale diagnostics book — attractive to a strategic that can absorb the macro and integrate the workflow, less attractive to a standalone holder paying 30x forward earnings for ~flat growth.

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print — Q3 FY2026, qtr ended 2026-03-31)

The latest 10-Q is the key fundamental document, filed 2026-05-06:

• Revenue: $311.4M vs $316.2M PY — −1.5% reported, −2% organic. Management bridge: a 2% FX tailwind and a 2% Exosome-divestiture headwind net out; underlying −2% organic. Stripping a one-time 3% headwind from two cell-therapy customers (FDA Fast Track) and 1% OEM order-timing → "adjusted" organic +2%. Read it as roughly flat-to-down underlying demand.
• Margins: GAAP gross margin 66.9% (Q3). GAAP operating income $75.5M vs $38.7M PY — the jump is optics: the prior-year quarter carried impairment/litigation charges, so the YoY "improvement" is a low base, not operating leverage.
• EPS: GAAP diluted $0.32 vs $0.14. Nine-month GAAP diluted $0.81 vs $0.57.
• Segments: Protein Sciences −4% organic; D&SB +3% organic with margin lifting to 12.1% post-Exosome. Spatial Biology mid-teens growth, COMET +65%, RNAscope high-single-digits.
• Guidance: ~flat organic in Q4 FY26; management flagged an expected emerging-biotech-spend uptick in 1H FY27 (2–3 quarter lag from a biotech-funding rebound). Note: the print missed consensus revenue and EPS per one transcript headline.
• Balance sheet (FY25 year-end reference): cash $162.2M; revolver drawn $346M ($654M undrawn on a $1B facility maturing Aug 2027); goodwill $980.9M (38% of assets); intangibles $365.6M; operating cash flow FY25 $287.6M; capex $31.0M → FCF ≈ $256.6M. AR fell to $206.9M (from $241.4M) and inventory $189.4M — no receivables/inventory blow-out.

Unusual vs own history: the standout is the FY25 GAAP operating-income collapse to $102.3M (8.4% margin) from $206.7M — driven by an $80.5M held-for-sale impairment + $41.8M "certain litigation" (arbitration) charge + $28.2M restructuring. Adjusted EPS held ($1.92 FY25 vs $1.77 FY24), so the cash earnings power is intact; the GAAP P&L was savaged by one-offs. The market's problem was never one-off charges — it was the structural top-line stall.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (transcripts/ empty) — this lens is ``-grounded and necessarily thinner.

• Tone trajectory (FY25 → Q3 FY26): progressively defensive. The recurring theme moved from "broad-based recovery" (FY25) to "emerging-biotech softness," "two-to-three-quarter lag," and explicit macro hedging (NIH cuts, tariffs) by Q3 FY26.
• What management added to the script: NIH administrative-cost caps, ~$18B proposed NIH cuts, and proposed 250% pharma tariffs as named demand risks — CFO Jim Hippel warned these "will stifle demand".
• What they kept saying: Spatial Biology / COMET as the secular bright spot; cell & gene therapy as the long-duration optionality; "ongoing profitability initiatives."
• What they stopped saying: confident organic-growth re-acceleration guidance — replaced by "approximately flat."
• Net: the sentiment arc is a management talking down near-term demand while defending the long-term franchise — classic setup that precedes a board agreeing to sell. The June 25 deal is the resolution of that arc.

Lens 7 · Comps

Peer multiples are ``, dated, and pulled from the same June-2026 sweep; treat as approximate. TECH's own multiples are now distorted by the deal (it trades on the $73 cash offer, not on fundamentals), so its trailing P/E of ~102x and EV/EBITDA ~31x are arb artifacts, not valuation signals.

Read: pre-deal, TECH at ~30x forward on ~flat growth was expensive vs the group (TMO/DHR/RVTY/QGEN at 16–22x forward) — a premium the market increasingly refused to pay as growth stalled, which is the activist's whole case. Merck's $73 (~30x the ~$1.85 FY27 EPS, or low-30s on FY26 ~$1.67) effectively pays the peak multiple in cash — a clean exit for holders, a full price for Merck justified only by synergies (€140M by yr 3) and strategic fit, not by standalone DCF. 5-year-average-ROE and per-peer dividend yields were not sourced and are deliberately left blank rather than fabricated.

Lens 8 · Stock-Price Catalysts (moves >5%, last ~5 years)

Mostly ``; pattern matters more than each tick.

• 2026-06-25 — the defining event: +19–24% in a day to ~$70 on the Merck $73 cash bid. Deutsche Bank cut to Hold on the news (deal-closed price = ceiling).
• 2025 (multiple legs down): NIH-funding shock. Trump administration NIH administrative-cost caps + proposed ~$18B NIH cuts repeatedly hit the stock; one session −~10–12%. A "Sell" initiation framed Q4 FY25 around NIH cuts + tariffs.
• Multi-year derating: shares fell ~50% over five years and ~20% in the trailing 52 weeks pre-deal — a textbook COVID-era-tools-bubble unwind compounded by funding cuts.
• Earnings reactions: the name has historically moved hard on organic-growth prints and guidance tone, not on EPS beats (adjusted EPS was resilient even as the stock fell). The market reacts to demand signals (academic/biotech funding, organic growth) — not to the bottom line. That is the single most useful behavioral fact: this is a sentiment-on-funding stock, which is why a strategic buyer (immune to quarterly funding noise) was the natural clearing buyer.

---

Phase C — Judge people & books

Lens 9 · Management

• Kim Kelderman — President & CEO since 2024-02-01 (with the company since 2018; prior: Thermo Fisher exec, Becton Dickinson segment leader). Took the chair into the teeth of the funding downturn; his tenure is defined by portfolio cleanup (Exosome divestiture, held-for-sale actions, restructuring) and ultimately negotiating the sale. Track record as standalone CEO is short and was judged by the market as insufficient to re-accelerate growth — hence activist pressure.
• James (Jim) Hippel — EVP & CFO since 2014 (prior: Mirion, Thermo Fisher, Honeywell, KPMG). Long-tenured, credible; the public voice on NIH/tariff risk.
• Segment heads: William Geist (Protein Sciences, since 2022; ex-Quanterix COO, ex-Thermo Fisher); Matthew McManus (D&SB, since 2024; ex-Azenta COO, ex-Asuragen CEO). Note the Thermo-Fisher pedigree across the C-suite — a tools-industry operating bench.
• Capital allocation history: acquisition-led growth (Lunaphore $169.7M FY24; Namocell $101.2M FY23; Spear Bio $15M FY25 investment). Returned capital: $50.4M/yr dividends ($0.32/share) + $275.7M buyback in FY25 (up sharply from $80M FY24). The big FY25 buyback near multi-year lows looks shareholder-friendly in hindsight. ROE/ROIC were depressed by the GAAP-charge year; on an adjusted basis the business still throws off ~$256M FCF.
• The Wilson Wolf overhang (capital-allocation watch-item): a contractual forward obligation to buy the remaining 80.1% of Wilson Wolf by 2027-12-31 for ~$1B + contingent consideration. That ~$1B liability lands in the same window as the $1B revolver's Aug-2027 maturity — a real balance-sheet pinch a standalone TECH would have had to fund. Under Merck's balance sheet it becomes trivial; another quiet reason the sale makes sense.
• Red flags: none of the promotional/related-party variety. The $41.8M FY25 arbitration/litigation charge is resolved, not recurring. CEO-transition charges in FY24 are normal. Founder vs professional: fully professional-manager, ex-strategic-operator archetype — which at this stage (mature, cyclical, activist-pressured) implies a sell-the-company outcome, exactly what happened.

Lens 10 · Forensic Red Flags

Acting as a forensic analyst over the income statement, balance sheet, and cash-flow statement [all figures research-layer unless tagged]:

• GAAP vs adjusted gap is large and worth watching. FY25 GAAP net income $73.4M vs non-GAAP adjusted net earnings $306.5M — a $233M wedge. The adjustments are mostly legitimate and non-cash/one-off (intangible amortization $75.3M, $80.5M impairment, $41.8M litigation, $28.2M restructuring, $42.2M SBC) — but SBC of ~$42M added back every year is a real, recurring economic cost the adjusted figure flatters. Quality-of-earnings caveat, not a fraud flag.
• Goodwill + intangibles = $1.35B (52% of $2.56B assets). Goodwill alone 38% of assets. An acquisition-rollup balance sheet; impairment risk is live (proven by the FY25 $83.1M D&SB impairment). Annual quantitative goodwill test in FY25 passed for all five reporting units.
• Cash flow vs earnings: operating cash flow $287.6M comfortably exceeds GAAP net income $73.4M (the gap is the non-cash charges) and approximates adjusted earnings — cash conversion is healthy; earnings are not being inflated relative to cash. This is the reassuring forensic signal.
• Receivables/inventory: AR down YoY, inventory only modestly up — no channel-stuffing or demand-pull-forward signature. Clean.
• Held-for-sale accounting: the recurring held-for-sale designations + impairments (Protein Sciences FY24, D&SB FY25) are aggressive portfolio pruning; they depress GAAP and inflate the adjusted-vs-GAAP gap. Legitimate but worth flagging as a pattern.
• Revenue recognition is KPMG's single Critical Audit Matter — flagged for dispersion across locations, not for aggressiveness. KPMG (auditor since 2002) issued an unqualified opinion on both the statements and ICFR.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: None. Zero LR and zero AAER naming Bio-Techne in the 2021-06-29 → 2026-06-29 window, verified via SEC EDGAR EFTS.
• 10-K Item 3 (Legal Proceedings): the company's own disclosure — "As of August 22, 2025, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect". The $41.8M FY25 litigation charge was an arbitration settlement/award, now resolved — not pending material litigation.
• Non-SEC enforcement (FTC/DOJ/FDA/CFPB): web search surfaced no material enforcement actions, consent decrees, or fines against Bio-Techne; the only regulatory items of substance are market-demand regulations (NIH funding, EU IVDR compliance costs, FDA LDT oversight) disclosed as risk factors, not enforcement.
• Deal-specific legal note: post-announcement merger-objection lawsuits (boilerplate "disclosure" suits) are near-certain for a deal this size and should be expected; none material as of this writing. Termination fee $230.5M payable by TECH under specified circumstances.
• Conclusion: No material regulatory or legal findings — verified via SEC EDGAR EFTS (LR, AAER), web search, and 10-K Item 3 as of 2026-06-29.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (governed by the deal, not a DCF)

Standalone EPS is now secondary to the deal-completion math, so this lens leads with the arb and keeps the fundamental projection as the deal-break reference.

Merger-arb return (the actual trade):

• Offer: $73.00 cash/share. Current: ~$71. Gross spread ≈ $2.00 (~2.8%).
• Assume close late 2026 / early 2027 → ~6 months → annualized ≈ 5.6% gross, plus any TECH dividend ($0.08/qtr) collected to close. A modest but positive spread implying the market prices a high (~85–90%) deal-close probability.
• Downside if deal breaks: unaffected price ~$58–59 (2026-06-24 close) and ~$53–54 (1-month VWAP implied by the 36% premium). So break risk ≈ −$12 to −$18 (−17% to −25%) from $71. Asymmetry is unattractive for a naked long here ($2 up vs ~$15 down) unless your deal-close probability is firmly >90%.

Standalone EPS path (the deal-break / no-deal reference), built from consensus + actuals:

• FY26 (ending 2026-06-30, ~done): non-GAAP EPS ~$1.67, down ~2% YoY (vs FY25 adjusted $1.92 reported in the 10-K — note the consensus figure uses a slightly different adjusted basis; the direction is the point: flat-to-down).
• FY27: consensus ~$1.85, +~11% YoY on an assumed biotech-spend recovery.
• FY28: ~$2.00–2.10, assuming low-to-mid-single-digit organic growth resumes + ~50bp/yr adjusted-margin recovery + buyback-driven share reduction. This is soft — it depends entirely on the funding cycle turning, which is the whole uncertainty.
• Base / bull / bear (standalone, no deal): Base ~$1.85 FY27 (funding stabilizes). Bull ~$2.05 (sharp biotech rebound, COMET/cell-therapy inflect). Bear ~$1.55 (NIH cuts + tariffs bite harder, organic stays negative into FY27).

Forecast log: Skipped per --watchlist rules — no forecast.ts create. And it would be the wrong instrument anyway: the scoreable binary here is "Merck/Bio-Techne deal closes at $73 by 2027-06-30," not an EPS line. (If promoted to a thesis, log that binary, p≈0.85.)

Lens 12 · Bull vs Bear

Bull case (now = "the deal closes"). $73 cash is a near-certain ~2.8% pickup with a hard catalyst and a credit-strong, strategically-motivated acquirer (Merck KGaA, IG-rated, financing in hand, €140M synergies, a serial life-science acquirer that bought Millipore and Sigma-Aldrich). The strategic logic is clean and complementary (ProteinSimple + cGMP proteins + RNAscope bolt onto MilliporeSigma's bioprocessing/CGT workflow) — meaning limited horizontal antitrust overlap, which lowers deal-break risk. Activist pressure + a willing board + a full premium = a motivated-seller dynamic that rarely unwinds.

Bear case (the deal breaks). Three permanent-impairment-flavored risks: (1) Regulatory block / delay — EU and especially China SAMR review of a German acquirer buying a US tools maker with China manufacturing in a tense US-China-EU trade environment is the live break risk; pharma-tariff/geopolitics could complicate. (2) MAC / financing wobble — a sharp further deterioration in the funding cycle or Merck's appetite (unlikely given all-cash + signed). (3) Standalone reality if it breaks — you own a ~flat-growth, ~30x-forward tools company in a funding recession, reverting to high-$50s. Pre-mortem (18 months out, thesis broke): SAMR/EU imposes remedies or blocks; deal terminates; TECH falls to ~$55; the $230.5M break fee is paid to Merck (not to holders); the funding cycle is still soft and TECH re-rates down toward peers' 18–22x. Multiples too high? On a standalone basis, yes — which is precisely why the board took cash. Contrarian view the market is underpricing: the ~2.8% spread looks thin for the China-regulatory tail — a cross-border German-buys-US-with-China-ops deal in 2026 is not a slam-dunk close, and the spread may be too tight for the antitrust-timeline risk (i.e., the market may be too sanguine, not too fearful).

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull (which is now "the deal closes") and the residual standalone bull:

• What structurally breaks the business (standalone): it is a leveraged bet on government + biotech R&D budgets. ~Academic/government + emerging-biotech demand is the swing factor, and both are under simultaneous pressure (NIH cuts, tariffs, biotech-funding winter). A tools supplier cannot out-execute a demand recession in its end-market.
• Concentration risk: customer concentration is genuinely low (<10% any name) — but end-market concentration is high (the academic/biotech research dollar). A single policy variable (NIH appropriations) moves a large slice of demand. That is a concentration the 10-K's "no customer >10%" framing hides.
• Why the moat is weaker than bulls think: outside the reagent core, ProteinSimple and spatial-biology instruments face well-funded competitors (10x Genomics, Bruker, Akoya, Standard BioTools in spatial; many in protein analysis), and instruments are capex-cyclical — exactly what slumps in a funding downturn.
• Most dangerous competitor bulls underrate: the scaled razor-blade compounders (Danaher/Cytiva, Thermo Fisher) who can cross-subsidize and out-distribute in a downturn — and now Merck KGaA itself if the deal failed, having seen the books.
• Worst capital-allocation move: arguably the Wilson Wolf forward — committing to ~$1B + contingent for a cell-culture-device maker, structured as a 2027 obligation, just as the cycle turned; it became a balance-sheet overhang that a standalone TECH would have had to fund into the Aug-2027 revolver maturity.
• Assumptions that must hold for the current ~$71 price: the Merck deal closes at $73 on schedule. That's it. Break the deal and ~25% downside is on the table.
• Growth disappoints by 20–30% (standalone): if FY27 organic stays negative instead of recovering, FY27 EPS is ~$1.55 not $1.85, and a de-rate to ~20x = ~$31 — a brutal standalone downside that the cash deal is rescuing holders from.
• Single scenario that permanently impairs: a hard, durable NIH/biotech funding regime change (multi-year real cuts) that resets the research-tools TAM lower — plausibility moderate and rising, and the clearest reason the board sold rather than fought.

Lens 14 · Management Questions (ordered by information value)

1. What is your assessed probability and expected timeline for Chinese SAMR and EU antitrust clearance of the Merck transaction, and what remedies (if any) have regulators signaled? (the single variable that governs the trade)
2. If the deal terminates, what is the standalone capital plan to fund the ~$1B Wilson Wolf forward obligation alongside the August 2027 revolver maturity?
3. Under what specified circumstances does the $230.5M termination fee trigger, and are there any financing or regulatory "outs" for Merck?
4. What organic growth and margin trajectory did the board model on a standalone basis that made $73 cash the value-maximizing outcome versus continuing independent?
5. How much of the Q3 FY26 −2% organic is cyclical (funding) versus structural (share loss), by division?
6. What is the real, durable consumable pull-through per COMET and per ProteinSimple instrument placed — i.e., the recurring razor-blade base growing under the install base?
7. Quantify direct + indirect exposure to NIH-funded demand and to the proposed pharma tariffs; what is the elasticity you actually observe?
8. What gives you confidence in a 1H-FY27 emerging-biotech rebound beyond the "2–3 quarter lag" heuristic — what leading indicators are you watching?
9. Post-Exosome, what further D&SB portfolio actions were contemplated, and at what margin/growth profile does the remaining diagnostics book settle?
10. What is the lot-to-lot switching cost in the reagent core in practice — what share of revenue is genuinely "sticky" validated demand vs re-competed each cycle?
11. Cell & gene therapy / ScaleReady: what is the current cGMP-protein + Wilson Wolf revenue run-rate, and its growth, separated from the research book?
12. How exposed is China-based manufacturing to the deal's geopolitics, and would a forced divestiture/carve-out be required for clearance?
13. What were the other bidders or strategic alternatives the board evaluated, and why was an all-cash strategic sale preferred to a standalone turnaround or a split?
14. What is the normalized adjusted operating margin at trough vs recovery, and how much is structurally recoverable vs mix-permanent?
15. What retention and integration commitments exist for the Protein Sciences scientific bench (the source of the reagent moat) under Merck ownership?

---